Whole genome sequencing for diagnosis of neurological repeat expansion disorders
Ellen M. McDonagh,
Katherine R Smith,
Antonio Rueda Martin,
Kailash P Bhatia,
James E Davison,
Laxmi Venkata Prasad Korlipara,
Mary M. Reilly,
Jonathan M. Schott,
Thomas T. Warner,
Nicholas W Wood,
Ana Lisa Taylor Tavares,
Genomics England Research Consortium,
Denise L Perry,
Patrick F. Chinnery,
Jenny C Taylor,
John A Sayer,
F Lucy Raymond,
Lyn S Chitty,
Zandra C Deans,
Mark J. Caulfield,
Michael A Eberle,
Ryan J Taft,
Posted 06 Nov 2020
bioRxiv DOI: 10.1101/2020.11.06.371716
Posted 06 Nov 2020
Background: Repeat expansion (RE) disorders affect ~1 in 3000 individuals and are clinically heterogeneous diseases caused by expansions of short tandem DNA repeats. Genetic testing is often locus-specific, resulting in under diagnosis of atypical clinical presentations, especially in paediatric patients without a prior positive family history. Whole genome sequencing (WGS) is emerging as a first-line test for rare genetic disorders, but until recently REs were thought to be undetectable by this approach. Methods: WGS pipelines for RE disorder detection were deployed by the 100,000 Genomes Project and Illumina Clinical Services Laboratory. Performance was retrospectively assessed across the 13 most common neurological RE loci using 793 samples with prior orthogonal testing (182 with expanded alleles and 611 with alleles within normal size) and prospectively interrogated in 13,331 patients with suspected genetic neurological disorders. Findings: WGS RE detection showed minimum 97.3% sensitivity and 99.6% specificity across all 13 disease-associated loci. Applying the pipeline to patients from the 100,000 Genomes Project identified pathogenic repeat expansions which were confirmed in 69 patients, including seven paediatric patients with no reported family history of RE disorders, with a 0.09% false positive rate. Interpretation: We show here for the first time that WGS enables the detection of causative repeat expansions with high sensitivity and specificity, and that it can be used to resolve previously undiagnosed neurological disorders. This includes children with no prior suspicion of a RE disorder. These findings are leading to diagnostic implementation of this analytical pipeline in the NHS Genomic Medicine Centres in England. ### Competing Interest Statement Genomics England Ltd is a wholly owned Department of Health and Social Care company created in 2013 to introduce WGS into healthcare in conjunction with NHS England. All Genomics England affiliated authors are, or were, salaried by or seconded to Genomics England. RJT, ME, ED, RTH are employees and shareholders of Illumina Inc.
- Downloaded 690 times
- Download rankings, all-time:
- Site-wide: 33,232
- In genomics: 2,950
- Year to date:
- Site-wide: 6,367
- Since beginning of last month:
- Site-wide: 5,396
Downloads over time
Distribution of downloads per paper, site-wide
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!